Latest FDA Proposal Could Ease Restrictions on Popular Peptide Drugs

The Food and Drug Administration, led by Secretary of Health Robert F. Kennedy Jr., is making waves with a new plan to increase access to unproven peptide drugs that have gained popularity within the Make America Healthy Again movement. However, FDA staff scientists have expressed concerns that these drugs have not undergone sufficient studies to prove their safety and efficacy, potentially causing harm.

An “interim access policy” for peptides has been submitted by the FDA for review by the White House, as revealed in a filing notice on the Office of Management and Budget’s website. While details of the policy are currently unavailable, insider sources have hinted that the proposal includes an “enforcement discretion” clause for certain peptide drugs. This discretion would indicate that the FDA may choose not to enforce existing restrictions on peptides, offering reassurance to specialty pharmacies looking to produce these drugs without fear of repercussion.

Despite repeated requests for comments, the Department of Health and Human Services, the governing body overseeing the FDA, remains silent on the matter.

This move comes amidst the FDA’s ongoing assessment of over a dozen injectable peptide drugs, widely popular yet lacking essential safety and efficacy data, posing a potential risk. These peptides have been excluded from compounding pharmacies, specialized establishments that provide customized medications, due to safety concerns raised by FDA scientists in 2023.

“Charlatans” and Misleading Claims

Despite these warnings, the popularity of these unverified peptide drugs continues to rise, with vendors peddling false claims of health benefits like enhanced appearance, increased vitality, and accelerated healing. Particularly favored among Make America Healthy Again supporters, influential figures within the movement are actively promoting peptide products. Kennedy, a self-proclaimed “huge fan” of peptides, has promised to challenge the FDA’s regulations on these drugs.

              </div>

Source: arstechnica.com